ARSENAM (Arsenic Trioxide)

Active ingredient: Arsenic Trioxide (As₂O₃)
Dosage form: Solution for intravenous infusion
Concentration: 1 mg/mL
Volume: 10 mL per vial
Packaging: Sterile vial in individual box

Disease Group:

Oncohematology

Acute Promyelocytic Leukemia (APL)

Цена: 342 ₽

Manufacturer: GLS Pharma Ltd., India Store between 15°C and 30°C in the original packaging, protected from light Prescription only; hospital use under strict medical supervision Manufactured in compliance with WHO-GMP standards

Description

Indications for use

Directions for use

Contraindications and side effects

How Does the Product Work? Who Is It Recommended For?

Mechanism of Action:
Arsenic trioxide exhibits antiproliferative activity, inducing apoptosis and differentiation in malignant cells. It affects mitochondrial function and intracellular signaling pathways involved in the survival of leukemic cells.

Recommended For:
Indicated for patients with acute promyelocytic leukemia (APL), particularly those with t(15;17) translocation and/or PML/RAR-α gene, who demonstrate sensitivity to arsenic-based therapies.

Acute promyelocytic leukemia (APL), relapsed or refractory
May be used in combination regimens or as monotherapy
Can be administered when all-trans retinoic acid (ATRA)-based therapies are not suitable or tolerated

Administered as a slow intravenous infusion
Recommended dose: 0.15 mg/kg body weight per day
Duration depends on treatment protocol: induction of remission followed by consolidation or maintenance
Infusion duration: 1 to 2 hours under medical supervision
Not for bolus injection

To be prescribed and administered only by a hematologist-oncologist in a hospital setting.

Contraindications: